Promising pathways for early detection, diagnosis, and prognosis of bladder cancer are provided by these biomarkers, which include the UBC® Rapid test, UBC ELISA kit, Xpert® Bladder Cancer Monitor, BC UroMark, TaqMan® Arrays, Soluble FAS (sFAS), Bladder tumor fibronectin (BTF), and IGF2 and MAGE-A3. This evidence concerns the gene FAS and urinary bladder cancer.